Drug intelligence / Profile preview

MVX-700

Development stage: Preclinical
Lead developer: MaveriX Oncology
Modality: Prodrugs/Conditional Activator Small Molecules → Small Molecules

Overview

MVX-700 is a conditionally activated small molecule drug conjugate (CA-SMDC) developed by MaveriX Oncology. It is designed to treat metastatic cancers, specifically metastatic urothelial carcinoma (mUC). The drug consists of an auristatin tyramine payload, which belongs to the microtubule inhibitor class of cytotoxics. The CA-SMDC platform allows for the selective delivery and activation of the payload within the tumor microenvironment, thereby potentially reducing systemic toxicity while maintaining potent anti-tumor activity through the disruption of microtubule dynamics and induction of cell death.

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on MVX-700.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVX-700.

Explore the full profile